Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-cohort, Phase II Study of SHR0302 Combined With PD-1/PD-L1 Inhibition for Treatment naïve or Acquired Resistant to Immunology NSCLC

NCT06925048 is registered in ClinicalTrials.gov with Chunxia Su as lead sponsor.

NCT NCT06925048
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06925048 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-cohort, Phase II Study of SHR0302 Combined With PD-1/PD-L1 Inhibition for Treatment naïve or Acquired Resistant to Immunology NSCLC
Lead sponsor
Chunxia Su
Phase
Phase 2
Overall status
Not yet recruiting
Start date
April 30, 2025
Completion date
December 31, 2027
Enrollment
86 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

immunology, jak inhibitor, non-small cell lung cancer